# Advancell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advancell-pty

- Industry: Biotechnology
- Headquarters: Sydney, Australia
- Website: www.advancell.com.au
- Total disclosed funding: $343M
- Latest round: Series D (Jun 30, 2026)
- Investors on record: 26

## About

Based in New South Wales, Australia, founded in 2019, Advancell Pty Ltd, also known as AdvanCell, operates as a radiopharmaceutical company. The company was founded by Andrew Adamovich. Currently, Philina Lee is serving as the CEO as of 2026. In June 2026, Advancell Pty Ltd raised USD 218.33 million in series D funding co-led by Ally Bridge Group and Alpha Wave Global, with participation from Bain Capital Life Sciences, Fidelity Investments, T Rowe Price, Qatar Investment Authority, Eventide Asset Management, and Velosity Capital, Eli Lilly & Company, Sanofi Ventures, Brandon Capital Partners, Morningside, SV Health Investors, Abingworth, SymBiosis Capital Management, Tenmile, Piper Sandler, Catalio Capital Management, Proto Axiom Pty Ltd, Time BioVentures.

AdvanCell’s product line includes Alpha 212®, which is a drug that is produced with the help of targeted alpha therapy technology that is used for the treatment of cancer; ²¹²Pb, which is an alpha isotope generator platform that develops therapeutic pipeline clinical programs including ADVC001 (prostate cancer), ADVC001 (melanoma), ADVC003 (pancreatic cancer and breast cancer); and The AdvanCell ²¹²Pb Generator, which is a technology that produces alpha radioligand treatments.

AdvanCell is a pre-commercial clinical-stage radiopharmaceutical company, so its revenue is primarily expected to come from a combination of partnership and licensing agreements with pharmaceutical companies, commercial sales of its targeted alpha therapy products (once approved), and manufacturing/isotope supply services built around its proprietary Lead-212 production platform. Public company disclosures emphasize its vertically integrated model, which combines isotope supply, radiopharmaceutical manufacturing, and drug development, suggesting future revenue opportunities from both therapeutic products and supplying/manufacturing radiopharmaceutical materials for internal and partner programs. The company has also highlighted collaborations with major pharmaceutical companies and investments in scalable isotope production and manufacturing infrastructure, indicating that partnership income, milestone payments, and eventual product commercialization are key components of its business model.

The company plans to use the June 2026 funding to support Phase 3 trials and expand U.S. manufacturing capacity.

## Funding rounds

- Series D, Jun 30, 2026, $218M — Abingworth, T Rowe Price, SV Health Investors, Brandon Capital Partners, Qatar Investment Authority, Fidelity Investments, Piper Sandler, Sanofi Ventures, Alpha Wave Global, Eli Lilly & Company, Ally Bridge Group, Eventide Asset Management, Morningside, Bain Capital Life Sciences, Time BioVentures, Catalio Capital Management, SymBiosis Capital Management, Tenmile, Proto Axiom Pty Ltd, Velosity Capital
- Series C, Feb 3, 2025, $112M — Abingworth, SV Health Investors, Brandon Capital Partners, 5Y Capital, Sanofi Ventures, Morningside, SymBiosis Capital Management, Tenmile
- Series B, Aug 12, 2022, $13M — 5Y Capital, Morningside, Perpetual Corporate Trust Limited, AGRICO PTY LTD, Greenseason Assets Pty Ltd, Hanning Nominees Pty Ltd, Votraint No 4 Pty Ltd

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B, Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B, Series C, Series D
- Perpetual Corporate Trust Limited — Series B
- AGRICO PTY LTD — Series B
- Greenseason Assets Pty Ltd — Series B
- Hanning Nominees Pty Ltd — Series B
- Votraint No 4 Pty Ltd — Series B
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series C, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series C, Series D
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series C, Series D
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series C, Series D
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series C, Series D
- Tenmile (https://capitalatlas.ai/funds/tenmile) — Series C, Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series D
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series D
- Eli Lilly & Company — Series D
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series D
- Bain Capital Life Sciences — Series D
- Time BioVentures (https://capitalatlas.ai/funds/time-bioventures) — Series D
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series D
- Proto Axiom Pty Ltd — Series D
- Velosity Capital — Series D